AUSAF (Australis Capital) Altman Z2-Score: 0.22 (As of Jun. 26, 2026)


What is Australis Capital Altman Z2-Score?

Australis Capital AUSAF -95.00% Altman Z2-Score is 0.22 as of Jun. 26, 2026.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Australis Capital has a Altman Z2-Score of 0.22, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Australis Capital's Altman Z2-Score or its related term are showing as below:


Australis Capital  (OTCPK:AUSAF) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Australis Capital Altman Z2-Score Related Terms


Australis Capital Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Australis Capital's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australis Capital Altman Z2-Score Chart

Australis Capital Annual Data
Trend Mar18 Mar19 Mar20 Mar21
Altman Z2-Score
-0.46 16.93 8.41 0.00

Australis Capital Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.94 0.00 -0.26 -1.49 -1.82

AUSAF vs ZTS, CTLT, VTRS: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australis Capital Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Australis Capital's Altman Z2-Score falls into.



Australis Capital Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Australis Capital's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0867+3.26*-0.9842+6.72*-0.2174+1.05*4.1163
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2021:
Total Assets was $56.60 Mil.
Total Current Assets was $9.51 Mil.
Total Current Liabilities was $4.61 Mil.
Retained Earnings was $-55.71 Mil.
Pre-Tax Income was -3.614 + -3.407 + -7.914 + 2.397 = $-12.54 Mil.
Interest Expense was -0.148 + -0.023 + -0.01 + -0.05 = $-0.23 Mil.
Total Liabilities was $10.29 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(9.513 - 4.606)/56.602
=0.0867

X2=Retained Earnings/Total Assets
=-55.705/56.602
=-0.9842

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-12.538 - -0.231)/56.602
=-0.2174

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(42.353 - 0)/10.289
=4.1163

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Australis Capital has a Altman Z2-Score of 0.22 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 0.22 mean?
Australis Capital (AUSAF) has a Altman Z2-Score of 0.22 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Australis Capital and its competitors.
Is Australis Capital's Altman Z2-Score too high?
Australis Capital's current Altman Z2-Score is 0.22. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Australis Capital's value of 0.22 is 94.3% below this industry median.
How does Australis Capital's Altman Z2-Score compare to ZTS and CTLT?
Australis Capital's Altman Z2-Score of 0.22 can be compared against companies in the Drug Manufacturers industry. The industry median Altman Z2-Score is 3.87. Australis Capital's value of 0.22 is 94.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australis Capital's current Altman Z2-Score of 0.22 is 94.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current Altman Z2-Score is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current Altman Z2-Score of 0.22. The current Altman Z2-Score is 0.22 and 94.3% below the Drug Manufacturers industry median of 3.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Australis Capital (AUSAF), the current Altman Z2-Score is 0.22 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.